NCT04365803 (BETTY) is a clinical trial of vacuum-assisted breast biopsy in Breast Cancer, sponsored by European Institute of Oncology.

Who is sponsoring NCT04365803?

NCT04365803 is sponsored by European Institute of Oncology.

What drugs are being tested in NCT04365803?

Interventions in NCT04365803: vacuum-assisted breast biopsy.

What condition does NCT04365803 study?

NCT04365803 studies Breast Cancer.

Is NCT04365803 still recruiting?

NCT04365803 is currently status unknown. Last updated 28 June 2023.

Last reviewed 2023-06-28 · How we verify

NCT04365803: BETTY

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Histology VABB-Histology Post Surgery Pilot Project (BETTY Trial)

Status unknown Last updated 28 June 2023

What this trial tests

trial testing vacuum-assisted breast biopsy in Breast Cancer in 22 participants. Status unknown.

Timeline

1 June 2018

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	European Institute of Oncology
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	22
Start date	1 June 2018
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	1 location across Italy

Drugs / interventions tested

vacuum-assisted breast biopsy

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

European Institute of Oncology

Who can join

Adults 18 to 99, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pilot study on patients with invasive ductal breast cancer triple negative or receptor tyrosine-protein kinase erbB-2 (HER2) overexpressed, any axillary lymphnodes status (any cN), candidates to neoadjuvant chemotherapy. The principal endpoint of the study will be the accuracy of the result of the histological examination of the Vacuum- Assisted Breast Biopsy (VABB) performed pre-surgery in comparison to the result of the histological examination of the definitive surgical intervention in patients with radiological complete response at Magnetic resonance imaging (MRI) done after the end of neoadjuvant chemotherapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Diagnostic performance of image-guided vacuum-assisted breast biopsy after neoadjuvant therapy for breast cancer: prospective pilot study.
Rossi EMC, Invento A, Pesapane F, Pagan E, et al · · 2023 · cited 9× · PMID 36477768 · DOI 10.1093/bjs/znac391

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other European Institute of Oncology trials

Trials by the same sponsor.

NCT07374809 — IMMUNOTHERAPY EFFICACY TARGETING ENDOMETRIAL CANCER · NA · not yet recruiting
NCT07429851 — CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors · recruiting
NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
NCT07508319 — Role of the Immune System in Preventing Laryngeal Cancer · recruiting
NCT07180693 — Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors: · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04365803 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by European Institute of Oncology
Last refreshed: 28 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04365803.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing